



Press Release
Ifosfamide Injection

Contact:

Suzanne Collier
Marketing Communications
888 TEVA USA

Teva Introduces Ifosfamide Injection

Irvine, California, July 26, 2007 – Teva Health Systems is pleased to announce the introduction and availability of Ifosfamide Injection. This product compares to Ifex[®]* Injection. Ifosfamide Injection is available in 50 mg/mL, 1 gm and 50 mg/mL, 3 gm single dose polymer vials.

“Teva’s Ifosfamide Injection is another example of our commitment to provide customers with quality, cost-effective products,” states Jonathan Zalk, Director of Marketing.

Teva Health Systems is a part of Teva Pharmaceuticals, the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.‡

* Ifex[®] is a registered trademark of Bristol-Myers Company.

‡ Data on file, Teva.

Please see accompanying prescribing information, including Boxed Warnings.